| Rank | Status | Study |
|---|
| 1 |
Recruiting
| A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV
| Condition: |
HIV Dementia |
| Interventions: |
Drug: Long acting methylphenidate; Drug: Matched placebo |
| Outcome Measures: |
Change in rate of reaction time as measured by neuropsychological testing; Number of Subjects with Adverse Events as Measures of Safety and Tolerability of Concerta in HIV infected adults |
|
| 2 |
Recruiting
| Effects of Methylphenidate (Ritalin®) on the Neural Basis of Anxiety
| Condition: |
PTSD |
| Interventions: |
Drug: Methylphenidate; Drug: Placebo |
| Outcome Measures: |
Changes in blood oxygenation level-dependent BOLD signal responses; Changes in BOLD signal responses; Changes in skin conductance response; Latency and accuracy during a interoceptive stimulus task |
|
| 3 |
Not yet recruiting
| The Effect of Ritalin (Methylphenidate Hydrochloride) on Pain and Auditory Sensitivity: an Exploratory Double-blind Randomized Controlled Trial on Healthy Subjects
| Condition: |
Pharmacological Action (PA) |
| Interventions: |
Drug: methylphenidate hydrochloride; Drug: Sugar pill (placebo) |
| Outcome Measures: |
Experimental pain intensity measured on a visual analogue scale (0-100); effect of Ritalin on auditory sensitivity, measured by the response to different auditory stimulations; pain intensity (NPS 0-100) in response to thermal stimuli and the measures of the auditory tests.
|
|
| 4 |
Not yet recruiting
| Identifying Characteristic Signature of Attention Deficit / Hyperactivity Disorder (ADHD) and Ritalin Treatment
| Condition: |
"Attention Deficit Hyperactivity Disorder" |
| Interventions: |
Drug: Ritalin; Drug: Placebo
|
| Outcome Measure: |
Resting oscillation activity and Event-related-Potentials in Attention Deficit / Hyperactivity Disorder (ADHD) and healthy subjects. |
|
| 5 |
Not yet recruiting
| Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
| Condition: |
Traumatic Brain Injury |
| Interventions: |
Drug: methylphenidate; Drug: Placebo |
| Outcome Measures: |
Relationship between tonic dopamine release (measured by displacement of [11C]-raclopride by oral methylphenidate) and change in processing speed between baseline and after methylphenidate treatment.; Relationship between D2/D3 receptor availability in ventral striatum and prefrontal cortex and neuropsychologic deficits.; Relationship between tonic dopamine release in the ventral striatum and prefrontal cortex with neuropsychologic deficits after TBI.; Relationship between D2/D3 receptor availability and functional connectivity of the prefrontal cortex with nodes of the default mode network.; Relationship between TMS-induced short-interval cortical inhibition of M1 and tonic dopamine release.; Test motivation and reward on and off methylphenidate in TBI patients. |
|
| 6 |
Unknown †
| Amantadine Versus Ritalin in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
| Condition: |
Attention Deficit Hyperactivity Disorder |
| Interventions: |
Drug: Amantadine; Drug: Ritalin
|
| Outcome Measure: |
The mean decrease in ADHD -RS-IV score from baseline will be used as the main outcome measure of response of ADHD treatment. |
|
| 7 |
Recruiting
| Methylphenidate to Improve Balance and Walking in MS
| Condition: |
Multiple Sclerosis |
| Interventions: |
Drug: Methylphenidate (Ritalin); Drug: Placebo
|
| Outcome Measures: |
Timed Up and Go time (TUG time); Automatic Postural Response (APR) Latency (in sec); Timed 25 Foot Walk (T25FW in secs); Pittsburgh Sleep Quality Assessment Questionnaire score; Modified Fatigue Index Scale score; Vestibular-Ocular Reflex time (in secs) |
|
| 8 |
Unknown †
| Study of Methylphenidate as Add on Therapy in Depressed Cancer Patients
| Condition: |
Depression |
| Interventions: |
Drug: Methylphenidate; Drug: Placebo |
| Outcome Measures: |
depressive symptoms; Distress level |
|
| 9 |
Recruiting
| Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study
| Conditions: |
Healthy; Substance-related Disorder; Mood Disorder |
| Interventions: |
Drug: Methylphenidate; Drug: Modafinil; Drug: MDMA; Drug: Placebo |
| Outcome Measures: |
Effect on amygdala and striatum BOLD signal responses to emotional stimuli; Effects on cognitive performance and associated BOLD signal changes in frontal areas; Subjective effects; Neuroendocrine effects; Empathy and social behavior; Physiological effects of methylphenidate, modafinil, and MDMA; Genetic Polymorphisms; Pharmacokinetics of methylphenidate, modafinil, and MDMA |
|
| 10 |
Recruiting
| Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders
| Conditions: |
Attention Deficit/Hyperactivity Disorder; Oppositional Defiant Disorder; Conduct Disorder |
| Interventions: |
Drug: Methylphenidate; Drug: Risperidone |
| Outcome Measures: |
Change from baseline of aggressive behaviors.; Clinical Global Impression - Improvement scale (CGI-I) questionnaire; ADHD-RS questionnaire; Children's Depression Rating Scale (CDRS) questionnaire; Young Mania Rating Scale (YMRS) questionnaire; Children Sleep Habits Questionnaire (CSHQ); Clinical Global Impression - Severity (CGI-S) questionnaire |
|
| 11 |
Recruiting
| The Effect of Methylphenidate Treatment in Familial Attention Deficit/Hyperactivity Disorder (ADHD)
| Conditions: |
Attention Deficit/Hyperactivity Disorder Combined Type; ADHD Predominantly Inattentive Type; ADHD Predominantly Hyperactivity Type; ADHD-not Other Specified |
| Intervention: |
Drug: Methylphenidate- Ritalin IR (Immediate Release)
|
| Outcome Measures: |
Clinical Global Impression-Improvement scale; overall ADHD-Rating Scale (ADHD-RS) score |
|
| 12 |
Recruiting
| Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis
| Conditions: |
Multiple Sclerosis; Fatigue |
| Interventions: |
Drug: Methylphenidate modified release; Drug: Maltodextrin |
| Outcome Measures: |
Change of Fatigue as measured by Fatigue Severity Scale; Change of Fatigue as measured by Modified Fatigue Impact Scale (MFIS) |
|
| 13 |
Not yet recruiting
| Methylphenidate on Intracortical Inhibition in Methamphetamine Abusers Attention Deficit Hyperactivity Disorder (ADHD)
| Condition: |
Attention Deficit Hyperactivity Disorder |
| Intervention: |
Other: methylphenidate tablets and Inter-stimulus Intervals (ISI) |
| Outcome Measures: |
Conners ADHD Rating Scale; Change of Motor Evoked Potential (MEP) |
|
| 14 |
Recruiting
| Control of Cognition
| Conditions: |
Healthy; Attention Deficit Hyperactivity Disorder; Alcohol Dependence; Attention Deficit Hyperactivity Disorder and Alcohol Dependence |
| Interventions: |
Drug: Methylphendiate; Drug: Naltrexone; Drug: Placebo |
| Outcome Measures: |
Identify abnormalities in prefrontal control neural circuits underlying attention control, motor control, and appetitive control; Characterize effects of methylphenidate and naltrexone on neural circuits in prefrontal cortex associated with attention control, motor control, and appetitive control; Reaction time on the Multi-Source Interference Task; Accuracy on the Multi-Source Interference Task; Reaction time variability on the Multi-Source Interference Task |
|
| 15 |
Recruiting
| Multimodal Therapy for Treatment of Fatigue
| Condition: |
Prostate Cancer |
| Interventions: |
Other: Placebo; Drug: Methylphenidate; Behavioral: Counseling Sessions; Other: Sham Exercise; Other: Standardized Exercise Intervention Program; Other: Cognitive Behavioral Therapy (CBT) |
| Outcome Measure: |
Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) subscale scores |
|
| 16 |
Recruiting
| Methylphenidate for Attention Problems After Pediatric TBI
| Conditions: |
Traumatic Brain Injury; TBI; ADHD |
| Interventions: |
Drug: Methylphenidate; Drug: Placebo |
| Outcome Measures: |
Parent report measures; Neuropsychological Testing; Teacher Report Measures |
|
| 17 |
Not yet recruiting
| Reversal of General Anesthesia With Methylphenidate
| Conditions: |
Post Operative Cognitive Dysfunction; Emergence From Anesthesia |
| Intervention: |
Drug: Methylphenidate |
| Outcome Measures: |
Number of Participants with Adverse Events as a Measure of Safety and Tolerability; Time to emergence from general anesthesia |
|
| 18 |
Recruiting
| Impact of CES1 Genotype on Metabolism of Methylphenidate
| Conditions: |
Carboxylesterase 1 (CES1) Genotype; CES1 Activity |
| Intervention: |
Drug: Methylphenidate |
| Outcome Measures: |
Plasma concentration of methylphenidate and Ritalinic acid; Metabolomic Profile
|
|
| 19 |
Recruiting
| A Comparison of Methylphenidate and Cognitive Behavioural Therapy for the Treatment of Binge Eating Disorder
| Condition: |
Binge-Eating Disorder |
| Interventions: |
Drug: Methylphenidate; Behavioral: Cognitive Behavioral Therapy |
| Outcome Measures: |
Frequency of binge episodes/days, as assessed by prospective daily binge diary; Frequency of objective binge episodes and overall illness severity, as assessed by both the Eating Disorder Examination Interview and Questionnaire; Clinician impression of illness severity and improvement, as assessed by the Clinical Global Impression scale; Quality of life, as assessed by the Quality of Life Inventory; Associated features of binge eating as captured by the Dutch Eating Behavior Questionnaire and Binge Eating Scale; Body Mass Index |
|
| 20 |
Not yet recruiting
| Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
| Conditions: |
Attention-deficit/Hyperactivity Disorder; Autism Spectrum Disorder |
| Intervention: |
Drug: Methylphenidate extended-release liquid formulation |
| Outcome Measure: |
Adult ADHD Investigator Symptom Report Scale (AISRS) |
|
